 , Adrenergic Agents , Adrenergic Uptake Inhibitors , Agents producing tachycardia , Agents that produce hypertension , Agents that reduce seizure threshold , Anticholinergic Agents , Antidepressive Agents , Antidepressive Agents, Tricyclic , Central Nervous System Agents , Central Nervous System Depressants , Combined Inhibitors of Serotonin/Norepinephrine Reuptake , Cytochrome P-450 CYP2B6 Inhibitors , Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) , Cytochrome P-450 CYP2D6 Inhibitors , Cytochrome P-450 CYP2D6 Inhibitors (moderate) , Cytochrome P-450 CYP2D6 Inhibitors (weak) , Cytochrome P-450 CYP2D6 Substrates , Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index , Cytochrome P-450 CYP2E1 Inhibitors , Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) , Cytochrome P-450 CYP2E1 Inhibitors (weak) , Cytochrome P-450 CYP3A Inhibitors , Cytochrome P-450 CYP3A4 Inhibitors , Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Substrates , Dibenzazepines , Drugs that are Mainly Renally Excreted , Enzyme Inhibitors , Heterocyclic Compounds, Fused-Ring , Histamine Antagonists , Histamine H1 Antagonists , Membrane Transport Modulators , Muscarinic Antagonists , Narrow Therapeutic Index Drugs , Nervous System , Neurotoxic agents , Neurotransmitter Agents , Neurotransmitter Uptake Inhibitors , Non-Selective Monoamine Reuptake Inhibitors , OCT1 inhibitors , OCT2 Inhibitors , P-glycoprotein inhibitors , Potential QTc-Prolonging Agents , Psychoanaleptics , Psychotropic Drugs , QTc Prolonging Agents , Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome , Serotonin 5-HT2 Receptor Antagonists , Serotonin 5-HT2A Receptor Antagonists , Serotonin Agents , Serotonin Modulators , Serotonin Receptor Antagonists , Tricyclics and Other Norepinephrine-reuptake Inhibitors